argenx SE (ARGX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARGX POWR Grades
- Value is the dimension where ARGX ranks best; there it ranks ahead of 57.67% of US stocks.
- ARGX's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
- ARGX's current lowest rank is in the Growth metric (where it is better than 2.81% of US stocks).
ARGX Stock Summary
- For ARGX, its debt to operating expenses ratio is greater than that reported by merely 6.02% of US equities we're observing.
- With a price/sales ratio of 29.05, Argenx Se has a higher such ratio than 94.48% of stocks in our set.
- Revenue growth over the past 12 months for Argenx Se comes in at 854.97%, a number that bests 98.84% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Argenx Se, a group of peers worth examining would be AKTS, CUE, VRNA, ACRS, and IMTX.
- Visit ARGX's SEC page to see the company's official filings. To visit the company's web site, go to www.argenx.com.
ARGX Stock Price Chart Interactive Chart >
ARGX Price/Volume Stats
| Current price | $323.10 | 52-week high | $356.78 |
| Prev. close | $315.97 | 52-week low | $249.50 |
| Day low | $313.63 | Volume | 318,700 |
| Day high | $323.67 | Avg. volume | 270,542 |
| 50-day MA | $311.01 | Dividend yield | N/A |
| 200-day MA | $304.69 | Market Cap | 17.32B |
argenx SE (ARGX) Company Bio
arGEN-X N.V., a clinical-stage biopharmaceutical company, focuses on creating and developing therapeutic antibodies for the treatment of cancer and autoimmune diseases. The company was founded in 2008 and is based in Breda, Netherlands.
Latest ARGX News From Around the Web
Below are the latest news stories about Argenx Se that investors may wish to consider to help them evaluate ARGX as an investment opportunity.
argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022February 24, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 3, 2022 at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website a |
argenx to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceFebruary 10, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. |
Garrison Bradford & Associates Inc Buys argenx SE, Apple Inc, Brookfield Asset Management ...New York, NY, based Investment company Garrison Bradford & Associates Inc (Current Portfolio) buys argenx SE, Apple Inc, Brookfield Asset Management Inc, Walmart Inc, sells Vanguard Short-Term Inflation-Protected Securities, PIMCO Dynamic Credit & Mortgage Income Fund, Essent Group, Aberdeen Asia-pacific Income Fund Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Garrison Bradford & Associates Inc. |
Argenx Se (ARGX) Receives a Buy from JMP SecuritiesIn a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Argenx Se (ARGX – Research Report), with a price target of $418.00. The company's shares closed last Thursday at $287.18. According to TipRanks.com, Butler is a 1-star analyst with an average return of -2.1% and a 37.2% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals. Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $380.69, which is a 34.1% upside from current levels. |
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agile Therapeutics (AGRX), Argenx Se (ARGX) and Liminal BioSciences (LMNL)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agile Therapeutics (AGRX – Research Report), Argenx Se (ARGX – Research Report) and Liminal BioSciences (LMNL – Research Report). Agile Therapeutics (AGRX) In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics, with a price target of $2.50. The company's shares closed last Wednesday at $0.34, close to its 52-week low of $0.34. According to TipRanks. |
ARGX Price Returns
| 1-mo | 12.21% |
| 3-mo | 12.84% |
| 6-mo | 16.93% |
| 1-year | 15.81% |
| 3-year | 152.98% |
| 5-year | 1,503.47% |
| YTD | -7.74% |
| 2021 | 19.08% |
| 2020 | 83.21% |
| 2019 | 67.09% |
| 2018 | 52.15% |
| 2017 | N/A |
Continue Researching ARGX
Want to do more research on Argenx Se's stock and its price? Try the links below:Argenx Se (ARGX) Stock Price | Nasdaq
Argenx Se (ARGX) Stock Quote, History and News - Yahoo Finance
Argenx Se (ARGX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...